|
|
|
SOUTH AFRICA: Indian first-line ARV registered
[This report does not necessarily reflect the views of the United Nations]
JOHANNESBURG, 26 April (PLUSNEWS) - Indian generic drug firm Cipla Medpro, this week announced one of its key antiretroviral (ARV) drugs had been registered in South Africa.
The drug Triomune - to be supplied through the local company, Enaleni Pharmaceuticals - was expected to help reduce the daily pill burden of HIV-positive patients from the current six or more tablets per day to only one pill in the morning and again at night.
"[This] is indeed a breakthrough and represents Cipla's commitment to making life-prolonging medicines accessible and affordable to the broader population," Trevor Edwards, CEO of Enaleni Pharmaceuticals said in a statement.
Triomune contains lamivudine, nevirapine and stavudine, which currently form part of first-line ARVs recommended by the South African Department of Health, and HIV Clinicians Society, as well as the World Health Organisation.
[ENDS]
:: MORE NEWS BRIEFS ::
|
|
|
 |
|
|
|
|
|
|
|
| Links |
AIDS Media Center
|
The Global Fund to fight AIDS, Tuberculosis & Malaria
|
International Community of Women Living with HIV/AIDS
|
AEGIS
|
International HIV/AIDS Alliance
|
PlusNews does not take responsibility for info in links supplied.
|
|
|
|
|
|
[Back] [Home Page]
Click here to send any feedback,
comments or questions you have about PlusNews Website or if you prefer you can
send an Email to Webmaster
Copyright IRIN 2006
The material contained on www.PlusNews.org comes to you via IRIN, a UN humanitarian news and information service, but may not necessarily reflect
the views of the United Nations or its agencies.
All PlusNews material may be reposted or reprinted free-of-charge; refer to the IRIN copyright page for conditions of use. IRIN is a project of the UN
Office for the Coordination of Humanitarian Affairs.
|